Selective inhibition of heparan sulphate and not chondroitin sulphate by a small, soluble competitive inhibitor

Marissa L. Maciej-Hulme1†*, Eamon Dubaisser2, Chun Shao3, Joseph Zaia3, Enrique Amaya2, Sabine L. Flitsch4 and Catherine L. R. Merry1†*

1 School of Materials, Materials Science Centre, The University of Manchester, Grosvenor St., Manchester M1 7HS, UK
2 Division of Cell Matrix Biology & Regenerative Faculty, Medicine of Biology, Medicine and Health, Michael Smith Building, The University of Manchester, Oxford Road, Manchester M13 9PT, UK
3 Center for Biomedical Mass Spectrometry, Boston University School of Medicine, 670 Albany Street, Boston, MA 02118
4 School of Chemistry & Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK

KEYWORDS: Heparan sulfate, azido sugar, glycosaminoglycan, carbohydrate biosynthesis, small molecule inhibitor

ABSTRACT: The glycosaminoglycan, heparan sulphate (HS), orchestrates many developmental processes. Yet its biological role has not yet fully been elucidated. Small molecule chemical inhibitors can be used to perturb HS function and these compounds provide cheap alternatives to genetic manipulation methods. However, existing chemical inhibition methods for HS also interfere with chondroitin sulphate (CS), complicating data interpretation of HS function. Herein, a simple method for the selective inhibition of HS biosynthesis is described. Using endogenous metabolic sugar pathways, Ac2GalNAz produces UDP-GlcNAz, which can target HS synthesis. Cell treatment with Ac2GalNAz resulted in defective chain elongation of the polymer and decreased HS expression. Conversely, no adverse effect on CS production was observed. The inhibition was transient and dose-dependent, affording rescue of HS expression after removal of the unnatural azido sugar. The utility of inhibition is demonstrated in cell culture and in whole organisms, demonstrating that this small molecule can be used as a tool for HS inhibition in biological systems.

Heparan sulphate (HS) is a prevalent glycosaminoglycan (GAG) attached to protein cores (proteoglycans) on the cell surface of almost every cell type. HS proteoglycans form an integral part of the extracellular matrix with important roles in development1, homeostasis2–3 and disease4–5. HS is involved in cell-cell and cell-matrix communication, fine tuning cellular responses to the extracellular milieu.

HS biosynthesis consists of a repeating disaccharide unit structure of glucuronic acid–N-acetylglucosamine (GlcA-GlcNAc) polymerized by the exostoses enzyme complex (EXT1/2) from UDP-GlcA and UDP-GlcNAc active nucleotide donor sugars6–8. During this process the N-deacetylase/N-sulphotransferase (NDST) enzymes work in tandem to begin modification of the nascent chain. The NDST enzymes can replace the acetyl group on GlcNAc with a sulphate9, often providing the gateway step for further modifications of the chain. Additionally, the NDSTs are also involved in control of HS chain length10 with NDST shown to be co-localised with EXT211. During extension of the backbone, several other chemical modifications are possible, resulting in fine patterning of the chain, where the functionality of HS is encoded. O-sulphotransferases (OSTs) modify the HS chain at the 2-, 6- and 3-O position or epimerisation of GlcA to iduronic acid (IdoA) by C5-epimerase can occur. Together, these enzymes contribute to HS functionality by influencing the fine patterning of the chain12.

Despite its widespread role in biology, few chemical tools exist for the manipulation of HS function, with those available often interfering with chondroitin sulphate/dermatan sulphate (CS/DS) pathways simultaneously. Methods to ablate HS exist; via targeted genetic deletion of biosynthetic HS enzymes6–7. However, genetic manipulation is costly and labour intensive with embryonic lethality in null mutant animals13, posing challenges for post-embryonic analysis. In contrast, chemical approaches offer cheap, user-friendly alternatives, which either perturb sulphation of the chain14,15 or compete with endogenous substrates involved in HS assembly, such as amino sugar derivatives15,16 and mimics of tetrasaccharide linkages17,18. However, the additional effect on CS/DS synthesis, can complicate data interpretation, particularly when both GAGs are displayed on the proteoglycan of interest19.

Azido sugars and other bio-orthogonal chemistry approaches have been demonstrated as useful functionalised chemical probes to label N-glycans20, O-GlcNAc modifications21,22, mucin type O-GalNAc glycans24 and sialic acid moieties25. Ac2GalNAz can be metabolically converted to UDP-GlcNAz and UDP-GalNAz via the GalNAc salvage pathway22, potentiating its use in GAG synthesis (Figure 1). The azido sugar nucleotide donors mimic UDP-GalNAc and UDP-GlcNAc, required for CS/DS and HS biosynthesis respectively.
Figure 1. Schematic of biological azido sugar precursor production for GAG synthesis. Ac4GalNAz travels across the cell membrane and enters the cytoplasm. Endogenous deacetylases remove the acetyl protective groups leaving GalNAz, ready to enter the GalNAc salvage pathway. After a cascade of enzymes, both UDP-GalNAz and UDP-GlcNAz are produced, which target CS/DS and potentially HS biosynthesis respectively.

Recently, the EXT1/2 enzyme complex has been shown to utilise UDP-GlcNAz as a substrate for the addition of GlcNAz to the non-reducing termini of heparan sulphate chains in vitro. However, in vivo, there is the potential that UDP-GlcNAz could interfere with the interaction or activity of the HS polymerisation machinery (EXT/NDST enzymes) due to the location of the azido group situated on the acetyl position of the GlcNAc residue, thereby producing an inhibitory effect on the biosynthetic pathway. Therefore, we sought to extend and validate the use of Ac4GalNAz treatment as a potential novel, small chemical inhibitor of HS synthesis.

RESULTS AND DISCUSSION

Chinese hamster ovary (CHO) cells were treated with different concentrations (7-35 µM) of Ac4GalNAz and cell surface HS was analysed using flow cytometry. A reduction in anti-(10E4) HS antibody staining was observed at the cell surface in response to increasing Ac4GalNAz concentration (Fig. 2).

To sustain the reduction of HS for longer periods, higher concentrations (35 µM) of azido sugar were required. Both 7 µM and 17.5 µM gave partial population decreases in 10E4 reactivity. Ac4GalNAz returned HS expression levels to match untreated cell populations (24h rescue), indicating that the effect of the azido sugar treatment on HS was transient and reversible. Significantly less HS was present in 35 µM Ac4GalNAz conditions compared with vehicle control conditions with HS depletion displaying a significant dose-dependent decrease (Fig. 3A).

Figure 2. Flow cytometric analysis of Ac4GalNAz-treated CHO cells. Cells were treated with 7-35 µM Ac4GalNAz for 24-48 hours, or for the first 24 hours, then 24 hours without Ac4GalNAz (24h rescue) and analysed for cell surface anti-HS (10E4) reactivity. Purple infilled, antibody control. Green trace, Ac4GalNAz-treated cells. Inset, experimental controls: purple infilled, antibody control; green trace, vehicle-treated; pink trace, untreated.

Figure 3 (A) Total relative abundance of HS from cell extract samples. (B) Percentage chemical modification contribution of HS and (C) percentage contribution of HS disaccharide species after RP-HPLC separation of 2-AMAC-tagged HS. Error bars represent SEM of N=3 independent experiments. *p≤0.05, **p≤0.01, student’s t test (two tailed).
Furthermore, HS biosynthesis was perturbed as a subtle, but significant change in disaccharide composition (Fig. 3B, C) showing alterations in the sulphation of the chain (increase in 6-O-sulphation and decrease 2-O-sulphation), reminiscent of GAG biosynthetic enzyme mutants. To elucidate changes in HS chain length, CHO cell cultures were radio-labelled with ³²H-glucosamine alongside treatment with Ac₄GalNAz and HS populations from cell extracts were purified as previously described. Total GAG synthesis was normalised to protein level (Supplementary Fig. 1). Radiolabelled studies showed a dose dependent decrease in chain length of HS (Table 1) in Ac₄GalNAz-treated cells compared to control. The marked decrease in chain length observed in both secreted HS and cell-derived HS populations after Ac₄GalNAz treatment (Table 1) suggests that early termination of chain synthesis was responsible for the depletion of HS at the cell surface observed in flow cytometric experiments (Fig. 2).

| Condition     | Secreted HS modal size (kDa) | Cell extract HS modal size (kDa) |
|---------------|------------------------------|---------------------------------|
| Vehicle control | 22                           | 8.5                             |
| 7 µM Ac₄GalNAz  | 12                           | 6.9                             |
| 35 µM Ac₄GalNAz | 7                            | 7.5                             |

Table 1. Chain length of radio-labelled HS.

Despite significant changes to HS chain synthesis, no incorporation of azido groups was detected in HS chains (data not shown), suggesting that either GlcNAz was not incorporated into the chain or that the azido was potentially removed by NDST activity during HS synthesis.

Due to convergence in their synthetic pathways (Fig 1.) and the utilisation of common precursors, chemical inhibitors usually affect both HS and CS/DS GAGs indiscriminately, therefore we assessed whether CS/DS synthesis was also inhibited by the same metabolic labelling strategy. Azido sugar labelling of CS proteoglycans using GalNAz has been described previously, but examination of the biosynthesis of CS/DS was not reported. No changes in CS/DS composition (Supplementary Figure 2), chain length (Supplementary Table 1) or quantity were observed (Supplementary Fig. 2), suggesting that the inhibitory effect of Ac₄GalNAz treatment was specific to HS synthesis. Ac₄ManNAz has also been reported to label CS proteoglycans, however the presence of CS-specific labelling on the proteoglycan was not investigated. Notably, no NDST enzymes are associated with CS/DS synthesis and the acetyl group of GalNAc remains unmodified; whereas HS biosynthesis specifically involves removal of the acetyl and N-sulphation of GlcNAc. This process, at least in part, controls HS chain length possibly via NDST interaction with EXT co-polymerase, although the mechanism is still unclear. EXT enzyme activity in vitro has been demonstrated to utilise UDP-GlcNAz as a substrate, suggesting that extension of the HS chain by the EXTs is likely to remain unaffected by GlcNAz in vivo. Thus, we hypothesise that the presence of GlcNAz interferes with normal NDST function, thereby inhibiting HS synthesis and resulting in truncated HS chains. Importantly, upregulation of NDST1 has been associated with chemoresistance in breast cancer and upregulated NDST1 activity increases HS biosynthesis. Thus, selective strategies for inhibition of HS activity, such as this one, may have therapeutic potential alongside current treatment options where HS is a known driver of chemoresistance and/or tumour growth.

Finally, since HS has been also demonstrated to play important roles in development, we sought to test the ability of the azido sugar to inhibit HS in a model organism. Therefore, a well-characterised and widely used developmental biology vertebrate model (Xenopus tropicalis) was utilised. Following treatment with the inhibitor, the abundance of total HS in Ac₄GalNAz-treated embryos was decreased compared with controls (Fig. 4A), confirming that this small, soluble inhibitor can be used in both organismal and cell culture-based experiments to inhibit HS synthesis. The Ac₄GalNAz-treated Xenopus embryos displayed a phenotypic short stature (Fig. 4B) accompanied with irregular somite boundaries and abnormal skeletal muscle orientation in a dose dependent manner, resulting in gross disorganization of the tail structure and tail kinks (Supplementary Fig. 3).

Interestingly, similar developmental abnormalities have been observed in XylAz-treated zebrafish, where GAG synthesis (CS and HS) was perturbed as a subtle, but significant change in disaccharide composition (Fig. 3B, C). Total HS (pmol) per embryo. (B) Embryo stature measurements of the tail extension (µm). + Ac₄GalNAz, 500 pmol injection and 500 µM soaking; + Ac₄GalNAc, 500 pmol injection and 500 µM soaking. *p≤0.05, **p≤0.001 + Ac₄GalNAz vs. Wildtype. One-way ANOVA with Turkey post-hoc comparison.

**CONCLUSIONS**

We propose that a common sugar analogue, Ac₄GalNAz, can be applied as a small, soluble and reversible chemical inhibitor of HS, which does not affect CS/DS biosynthesis, offering a new tool for HS inhibition. Ac₄GalNAz can be synthesised from inexpensive compounds and is commercially available. Using this strategy, HS inhibition can be achieved in cell-based assays and in whole organisms. The effect of Ac₄GalNAz on HS production is transient (Fig. 2), enabling flexible application and removal in experiments without the

![Figure 4. Ac₄GalNAz treatment of Xenopus embryos.](image-url)
need for gene manipulation. This novel selective HS inhibitor therefore may be used to probe HS biology in separation from CS/DS to identify HS-mediated mechanisms in biological systems for further investigation.

**MATERIALS AND METHODS**

**Cell culture, Ac-GalNAz and D-[6-3H]-glucosamine treatment.** CHO cells were cultured at 37°C/5% CO2 humidified conditions in Dulbecco’s Modified Eagle Medium:F12 Nutrient Mix (Ham) media (Invitrogen) supplemented with 10% v/v FBS (batch-tested, Biosera) and 2 mM L-glutamine (PAA). Cell culture medium was supplemented with sugars dissolved in DMSO: Ac-GalNAz (Molecular Probes), Ac-GalNAc (Flitsch group). For radioiodination experiments CHO cells were supplemented with 50 µCi D-[6-3H]-glucosamine hydrochloride (Perkin Elmer). CHO cells were seeded at 40,000 cells/cm² and then cultured for 48 hours for metabolic incorporation of the radiolabelled sugar.

**Flow cytometry.** To preserve the cell surface, non-enzymatic cell dissociation buffer (Gibco) was used to remove CHO’s tissue culture plastic. After washing with PBS, cells were incubated with anti-HS (F58-10E4) (1:200, Seigakagu) in 0.2% (w/v) BSA, followed by AlexaFlour goat anti-mouse IgM (k) (488 (1:1000, Molecular Probes). Cells were fixed with 1% PFA for 10 mins at room temperature before analysis (Becton Coulter Cyan ADP cytometer using CellQuest Pro software).

**GAG collection and purification.** Cell membranes were dispersed with 1% Triton X-100 in PBS with gentle agitation for 1-2 hours. Proteins were digested with 100 µg/mL Pronase (Streptomyces griseus from Biomedical Technologies, Inc.) for 4 hours at 37°C. DEAE anion-exchange chromatography for GAG preparations with step elution of HS and CS was performed using 1.5 M NaCl wash, used to isolate GAG material as previously described, with the exception of the radiolabelled GAG preparations where gradient anion exchange chromatography (0-1.5 M NaCl) was used. GAG samples were desalted using PD10 columns (GE Healthcare) and lyophilised.

**HS and CS chain length analysis.** Purified D-[6-3H]-radiolabelled HS or CS material was treated with 50 mM NaOH/1 M NaBH₄ at 45°C for 48 hours to cleave the protein stub from the xylose residue. Samples were neutralized with glacial acetic acid and then separated on Sepharose CL-6B columns in 0.2 M ammonium bicarbonate at a flow rate of 0.2 mL/min. 1 mL fractions were collected in pony vials (Sigma) and 2 mL Optimax scintillation fluid (Perkin Elmer) was added. Samples were sealed and shaken before processing for ³H radioactivity (counts per minutes) using a liquid scintillation counter (Wallac 1409). Modal chain length was estimated by comparison of Kav values with a calibration curve.

**Generation of GAG disaccharide species.** Purified GAG samples were digested either with 2 µl of each heparinase I-III (Iduron) in 0.1 M sodium acetate, 0.1 mM calcium acetate, pH 7.0 or with chondroitinase ABC (Amsbio) in 50 mM tris, 50 mM NaCl, pH 7.9 for 16 hours at 37°C. 2-AMAC labelling and RP-HPLC separation of HS disaccharides. HS disaccharides were labelled with 2-aminoacridone (2-AMAC) and separated using RP-HPLC as previously described using correction factors for the batch of 2-AMAC utilised. Data was also used to calculate the HS sulphation modification.

**SAX-HPLC separation of CS disaccharides.** D-[6-3H]-CS disaccharides were separated on a Hypersil 5 µm SAX column (Thermo Scientific) with a gradient of 0.15 M-0.7 M NaCl pH 3.5 over 47 minutes at a flow rate of 1 mL/min.

**Sugar microinjection and incubation of Xenopus embryos.** Fertilised NF stage 1 embryos in injection buffer (1% (w/v) Ficol in 0.1x Modified Marc Ringers, (MMR), pH 8) were injected with 1-5 nL of 500-1000 picomoles Ac-GalNAz or Ac-GalNAc (dissolved in 0.2 mM KCl) into the cytoplasm using a heat-pulled borosilicate glass capillary injection needle (1 mm x 0.78 mm, Harvard apparatus). Embryos were left to recover in injection buffer for 1-2 hours (stage 7-8) at 28°C before they were transferred to fresh agarose-coated dishes containing a bath of 0.500 µM Ac-GalNAz or Ac-GalNAc in 0.01x MMR solution. Embryos were incubated at 23°C (prior to gastrulation) for the first day of development, then at 25°C and transferred to fresh salmon/0.01x MMR conditions daily.

**Purification of Xenopus HS.** Embryos were lyophilised and ground in a pestle and mortar with 1 mL of PBS before addition of 1 mg/mL Pronase in 50 mM Tris/HCl pH 8, 1 mM CaCl₂, 1% Triton X-100. Proteins were digested for 16 hours at 55°C, then a further 0.5 mg Pronase was added and the digestion continued overnight. Pronase was heat-inactivated at 100°C for 10 mins and samples were then treated with 2 µL of 2 M MgCl₂ and 0.5 µL Benzonase Nuclease (300 mU, Sigma) at 37°C for 3 hours before adjustment to 0.5 M NaOH and mixing overnight. Formic acid was used to adjust the pH to 5.0 prior to centrifugation at 13,000 rpm. The supernatant was diluted with HPLC grade water and applied to DEAE anion exchange chromatography as described with the following alterations: DEAE beads were washed only with HPLC grade water prior to sample application and samples were eluted with 1 M NaCl, 20 mM NaOAc pH 6.0. The eluant was desalted using PD10 columns according to the manufacturer’s instructions.

**Mass spectrometry analysis of Xenopus HS disaccharides.** Xenopus HS disaccharides were diluted in 200 µL HPLC grade water and centrifuged at 12,000 rpm for 10 mins to remove insoluble material. Residual salts and/or proteins were removed from the supernatant using size-exclusion chromatography (Beckman SEC offline fractionation), followed by further clean up using a porous graphite carbon C-18 TopTip (Gligen) prior to LC-MS using a Dionex GlyceranPac AXH-1 (1mm x 15cm) (ThermoFisher) on an Agilent QTOF 6520 in negative mode, with an acquisition range of 100-1700 m/z. UAS2-GlcNCOEt6S (V-lab) was spiked into all samples as an external standard to monitor the spray conditions and used for normalization between samples.

**Whole mount antibody fluorescent imaging.** Embryos were fixed in 0.1 M MOPS pH 7.4, 2 mM EGTA, 1 mM MgSO₄, 3.7% (v/v) formaldehyde for 16 hours at 4°C before dehydration with 100% methanol. Embryos were then rehydrated by gradient dilution of the methanol with H₂O and antibody staining was performed as previously described using mouse 12/101 IgG1 (1:200, Developmental Studies HybriDoma Bank) followed by AlexaFluor goat anti-mouse IgG (H+L)-594 (1:500, Molecular Probes). Embryos were imaged using a glass-bottomed dish (MatTek Corporation) and imaged by confocal microscopy (Olympus Fluoview FV-1000).
ASSOCIATED CONTENT

Supplementary Materials
File name: Maciej-Hulme et al. Supplementary materials.PDF

AUTHOR INFORMATION

Corresponding Authors:
*cathy.merry@nottingham.ac.uk, marissa.maciej-hulme@radboudumc.nl

Present Addresses
1 Radboudumc, Geert Grootplein 10, 6525 GH Nijmegen, The Netherlands.
2 Nottingham Biodiscovery Institute, University Park, Nottingham. NG7 2RD, United Kingdom.

Author Contributions
Conceptualisation: MLMH, CLRM; Methodology: MLMH.; Validation: MLMH, CS; Formal analysis: MLMH.; Investigation: MLMH, CS, ED; Writing - original draft: MLMH.; Writing - review & editing: MLMH, CLRM, SLF, EA, ED, JZ, CS.; Supervision: JZ, SLF, EA, CLRM; Project administration: CLRM.; Funding acquisition: EA, CLRM.

Funding Sources
This work was supported by a BBSRC DTC Studentship Grant No. 978724 and MRC grant (MR/L007525/1).

ACKNOWLEDGMENTS

The authors would like to thank Robert Lea for technical support throughout the generation of the Xenopus data and Dr. Santanu Mandal for per-acetylation of GalNAC (AcGalNAC).

ABBREVIATIONS

GAG, glycosaminoglycan; HS, heparan sulfate; CS, chondroitin sulfate; AcGalNAC, peracylated N-acidolgalactosamine, NDST, N-deacetylase/N-sulphotransferase; IdoA, iduronic acid; 2-AMAC, 2-amino-16-carboxylic acid.

REFERENCES

1. Hacker, U.; Nybakken, K.; Perrimon, N., Heparan sulfate proteoglycans: The sweet side of development. Nature Reviews Molecular Cell Biology 2005, 6 (7), 530-541.
2. Wrenshall, L. E.; Platt, J. L., Regulation of T cell homeostasis by heparan sulfate-bound IL-21. Journal of Immunology 1999, 163 (7), 3793-3800.
3. Coulson-Thomas, V. J.; Gesteira, T. F.; Esko, J.; Kao, W., Heparan Sulfate Regulates Hair Follicle and Sebaceous Gland Morphogenesis and Homeostasis. Journal of Biological Chemistry 2014, 289 (36), 25211-25226.
4. Lindahl, U.; Kjellen, L., Pathophysiology of heparan sulfate: many diseases, few drugs. Journal of Internal Medicine 2013, 273 (6), 555-571.
5. Gomes, A. M.; Stelling, M. P.; Pavao, M. S. G., Heparan Sulfate and Heparanase as Modulators of Breast Cancer Progression. Biomed Research International 2013.
6. Lin, X.; Wei, G.; Shi, Z. Z.; Dryer, L.; Esko, J. D.; Wells, D. E.; Matzuk, M. M., Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Developmental Biology 2008, 224 (2), 299-311.
7. Stickens, D.; Zak, B. M.; Rougier, N.; Esko, J. D.; Werb, Z., Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development 2005, 132 (22), 5055-5068.
8. McCormick, C.; Duncan, G.; Goutsos, K. T.; Tufaro, F., The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proceedings of the National Academy of Sciences of the United States of America 2000, 97 (2), 668-673.
9. Bengtsson, J.; Eriksson, I.; Kjellen, L., Distinct effects on heparan sulfate structure by different active site mutations in NDST-1. Biochemistry 2003, 42 (7), 2110-2115.
10. Deligny, A.; Dierker, T.; Dagav, A.; Lundequist, A.; Eriksson, I.; Nairn, A. V.; Moremen, K. W.; Merry, C. L. R.; Kjellen, L., NDST2 (N-Deacetylase/N-Sulfotransferase-2) Enzyme Regulates Heparan Sulfate Chain Length. Journal of Biological Chemistry 2016, 291 (36), 18600-18607.
11. Presto, J.; Thuveson, M.; Carlsson, P.; Busse, M.; Wilen, M.; Eriksson, I.; Kusche-Gullberg, M.; Kjellen, L., Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation. Proceedings of the National Academy of Sciences of the United States of America 2008, 105 (12), 4751-4756.
12. Saissekharam, R.; Venkataraman, G., Heparin and heparan sulfate: biosynthesis, structure and function. Current Opinion in Chemical Biology 2020, 46, 626-631.
13. Dietrich, C. P.; Nader, H. B.; Buonassisi, V.; Colburn, P., Inhibition of Synthesis of Heparan-Sulfate by Seleunate - Possible Dependence on Sulfation for Chain Polymerization. Faseb Journal 1988, 2 (1), 56-59.
14. Greve, H.; Cuilty, Z.; Blumberg, P.; Kresse, H., Influence of Chlorate on Proteoglycan Biosynthesis by Cultured Human-Fibroblasts. Journal of Biological Chemistry 1988, 263 (26), 12886-12892.
15. Kiselevsky, R.; Szarek, W. A.; Ainsc, J. B.; Elinova, E.; Marone, S.; Bhat, S.; Berkin, A., Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose - Implications for the treatment of various amyloidoses. American Journal of Pathology 2004, 164 (6), 2127-2137.
16. van Wijk, X. M. R.; Oosterhof, A.; van den Broek, S. A. M. W.; Griffioen, A. W.; ten Dam, G. B.; Rutjes, F. P. J. T.; van Delft, F. L.; van Kuppevelt, T. H., A 4-deoxy analogue of N-acetyl-D-glucosamine inhibits heparan sulfate expression and growth factor binding in vitro. Experimental Cell Research 2010, 316 (15), 2504-2512.
17. Beahm, B. J.; Dehnert, K. W.; Derr, N. L.; Kuhn, J.; Eberhart, J. K.; Spillmann, D.; Amacher, S. L.; Bertozzi, C. R., A Visualizable Chain-Terminating Inhibitor of Glycosaminoglycan Biosynthesis in Developing Zebrafish. Angewandte Chemie-International Edition 2014, 53 (13), 3347-3352.
18. Kanwar, Y. S.; Hashall, V. C.; Jakubowski, M. L.; Gibbons, J. T., Effect of Beta-D-Xylose Substitute on the Glomerular Proteoglycans. J. Biochemical-Studies. Journal of Cell Biology 1984, 99 (2), 715-722.
19. Gard, D. R.; Tran, V. M.; Victor, X. V.; Koketsu, M.; Kubera, B., Inhibition of Heparan Sulfate and Chondroitin Sulfate Proteoglycan Biosynthesis. Journal of Biological Chemistry 2008, 283 (43), 28881-28887.
20. Tsuzuki, Y.; Nguyen, T. K. N.; Garud, D. R.; Kubera, B.; Koketsu, M., 4-Deoxy-4-fluoro-xylose derivates as inhibitors of glycosaminoglycan biosynthesis. Bioorganic & Medicinal Chemistry Letters 2010, 20 (24), 7269-7273.
21. Esko, J. D.; Lindahl, U., Molecular diversity of heparan sulfate. Journal of Clinical Investigation 2001, 108 (2), 169-173.
22. Breidenbach, M. A.; Gallaghcr, J. E. G.; King, D. S.; Smart, B. P.; Wu, P.; Bertozzi, C. R., Targeted metabolic labeling of yeast N-glycans with unnatural sugars. Proceedings of the National Academy of Sciences of the United States of America 2010, 107 (9), 3988-3993.
23. Boyce, M.; Carrico, I. S.; Ganguli, A. S.; Yu, S.-H.; Hangauer, M. J.; Hubbard, S. C.; Kohler, J. J.; Bertozzi, C. R., Metabolic cross-talk allows labeling of O-linked beta-N-acetylglucosamine-modified proteins via the N-acetylglucosamine salvage pathway. Proceedings of the National Academy of Sciences of the United States of America 2011, 108 (8), 3141-3146.
24. Debets, M. F.; Tastan, O. Y.; Wisnovsky, S. P.; Malaker, S. A.; Angelis, N.; Moekel, K. R. L.; Choi, J.; Plian, H.; Wagner, L. J. S.; Bineva-Todd, G.; Antonopoulos, A.; Ciocca, A.; Browne, W. M.; Li, Z.;
Briggs, D. C.; Douglas, H. L.; Hess, G. T.; Agbay, A. J.; Roustan, C.; Kjaer, S.; Haslam, S. M.; Snijders, A. P.; Bassik, M. C.; Moerner, W. E.; Li, V. S. W.; Bertozzi, C. R.; Schumann, M. A.; Metabolic precision labeling enables selective probing of O-linked N-acetylgalactosamine glycosylation. *Proc Natl Acad Sci U S A* 2020, 117 (41), 25293-25301.

25. Yang, L. F.; Nyalwidihe, J. O.; Guo, S. Q.; Drake, R. R.; Semmes, O. J., Targeted Identification of Metastasis-associated Cell-surface Sialoglycoproteins in Prostate Cancer. *Molecular & Cellular Proteomics* 2011, 10 (6).

26. Wu, Z. L.; Huang, X.; Ethen, C. M.; Tajte, T.; Pasek, M.; Zaia, J., Non-reducing end labeling of heparan sulfate via click chemistry and a high throughput ELISA assay for heparanase. *Glycobiology* 2017, 27 (6), 518-524.

27. Merry, C. L. R.; Bullock, S. L.; Swan, D. C.; Backen, A. C.; Lyon, M.; Beddington, R. S. P.; Wilson, V. A.; Gallagher, J. T., The molecular phenotype of heparan sulfate in the Hs2st(-/-) mutant mouse. *Journal of Biological Chemistry* 2001, 276 (38), 35429-35434.

28. Bai, X. M.; Esko, J. D., An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation. *Journal of Biological Chemistry* 1996, 271 (30), 17711-17717.

29. Merry, C. L.; Lyon, M.; Deakin, J. A.; Hopwood, J. J.; Gallagher, J. T., Highly sensitive sequencing of the sulfated domains of heparan sulfate. *J Biol Chem* 1999, 274 (26), 18455-62.

30. Laughlin, S. T.; Bertozzi, C. R., In Vivo Imaging of Caenorhabditis elegans Glycans. *Acs Chemical Biology* 2009, 4 (12), 1068-1072.

31. Hang, H. C.; Yu, C.; Kato, D. L.; Bertozzi, C. R., A metabolic labeling approach toward proteomic analysis of mucin-type O-linked glycosylation. *Proceedings of the National Academy of Sciences of the United States of America* 2003, 100 (25), 14846-14851.

32. Loebel, C.; Kwon, M. Y.; Wang, C.; Han, L.; Mauck, R. L.; Burdick, J. A., Metabolic Labeling to Probe the Spatiotemporal Accumulation of Matrix at the Chondrocyte-Hydrogel Interface. *Adv Funct Mater* 2020.

33. He, D. X.; Gu, X. T.; Li, Y. R.; Jiang, L.; Jin, J.; Ma, X., Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. *FEBS J* 2014, 281 (20), 4718-30.

34. Amaya, E.; Offield, M. F.; Grainger, R. M., Frog genetics: Xenopus tropicalis jumps into the future. *Trends Genet* 1998, 14 (7), 253-5.

35. Laughlin, S. T.; Bertozzi, C. R., Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation. *Nature Protocols* 2007, 2 (11), 2930-2944.

36. Guimond, S. E.; Puvarajesinghe, T. M.; Skidmore, M. A.; Kalus, I.; Dierks, T.; Yates, E. A.; Turnbull, J. E., Rapid purification and high sensitivity analysis of heparan sulfate from cells and tissues: toward glycomics profiling. *J Biol Chem* 2009, 284 (38), 25714-22.

37. Wasteson, A., A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate. *J Chromatogr* 1971, 59 (1), 87-97.

38. Deakin, J. A.; Lyon, M., A simplified and sensitive fluorescent method for disaccharide analysis of both heparan sulfate and chondroitin/dermatan sulfates from biological samples. *Glycobiology* 2008, 18 (6), 483-91.

39. Holley, R. J.; Ellison, S. M.; Fil, D.; O'Leary, C.; McDermott, J.; Senthivel, N.; Langford-Smith, A. W. W.; Wilkinson, F. L.; D'Souza, Z.; Parker, H.; Liao, A.; Rowston, S.; Gleitz, H. F. E.; Kan, S. H.; Dickson, P. I.; Bigger, B. W., Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. *Brain* 2018, 141 (1), 99-116.

40. Dubaisi, E.; Rousseau, K.; Lea, R.; Soto, X.; Nardeosingh, S.; Schweickert, A.; Amaya, E.; Thornton, D. J.; Papalopulu, N., A secretory cell type develops alongside multiciliated cells, ionocytes and goblet cells, and provides a protective, anti-infective function in the frog embryonic mucociliary epithelium. *Development* 2014, 141 (7), 1514-1525.